Antiseizure Medications - Oxcarbazepine Step Therapy Policy
Defines step therapy requirements for coverage of oxcarbazepine products under Cigna-administered health benefit plans, specifying Step 1 (generic oxcarbazepine tablets and oral suspension) and Step 2 (Oxtellar XR and Trileptal brand and generic) and criteria for approval.
Policy name changed from 'Antiseizure Medications - Oxtellar XR, Trileptal Step Therapy' to 'Antiseizure Medications - Oxcarbazepine Step Therapy Policy'.
Generic oxcarbazepine extended-release tablets were added to the policy as a Step 2 medication.
Annual revisions with 'No criteria changes' on multiple review dates.
Coverage Summary
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.